Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GEM-CLARIDEX: Lenalidomide and Dexamethasone (Ld) Versus Clarithromycin / Lenalidomide [Revlimid®] / Dexamethasone (BiRd) as Initial Therapy in Multiple Myeloma

NCT02575144 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT02575144
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02575144 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GEM-CLARIDEX: Lenalidomide and Dexamethasone (Ld) Versus Clarithromycin / Lenalidomide [Revlimid®] / Dexamethasone (BiRd) as Initial Therapy in Multiple Myeloma
Lead sponsor
PETHEMA Foundation
Phase
Phase 3
Overall status
Unknown status
Start date
September 30, 2015
Completion date
October 31, 2024
Enrollment
286 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma